Last reviewed · How we verify
IDP-124 Lotion — Competitive Intelligence Brief
phase 3
Topical corticosteroid and vitamin D analog combination
Vitamin D receptor (VDR) and glucocorticoid receptor (GR)
Dermatology
Small molecule
Live · refreshed every 30 min
Target snapshot
IDP-124 Lotion (IDP-124 Lotion) — Bausch Health Americas, Inc.. IDP-124 is a topical lotion formulation combining calcipotriene and betamethasone dipropionate to reduce inflammation and normalize skin cell differentiation in psoriasis.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| IDP-124 Lotion TARGET | IDP-124 Lotion | Bausch Health Americas, Inc. | phase 3 | Topical corticosteroid and vitamin D analog combination | Vitamin D receptor (VDR) and glucocorticoid receptor (GR) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Topical corticosteroid and vitamin D analog combination class)
- Bausch Health Americas, Inc. · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- IDP-124 Lotion CI watch — RSS
- IDP-124 Lotion CI watch — Atom
- IDP-124 Lotion CI watch — JSON
- IDP-124 Lotion alone — RSS
- Whole Topical corticosteroid and vitamin D analog combination class — RSS
Cite this brief
Drug Landscape (2026). IDP-124 Lotion — Competitive Intelligence Brief. https://druglandscape.com/ci/idp-124-lotion. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab